Archive for the ‘Asthma’ Category - Part 2

Reduction of Eosinophilic Inflammation in the Airways: Tolerability

There were no significant differences between montelukast and placebo in the frequency of clinical and laboratory adverse effects. While 27 patients were receiving montelukast, 13 patients reported a total of 26 clinical adverse effects; in comparison, 15 of 28 patients reported a total of 30 clinical adverse effects while receiving placebo. Respiratory events, especially cold […]

Reduction of Eosinophilic Inflammation in the Airways: PEF

Evening PEF increased significantly with monte-lukast treatment from 438.1 ± 102.5 L/min to 455.4 ± 100.6 L/min (p < 0.005) at 2 weeks and to 464.3 ± 99.0 L/min (p < 0.0005) at 4 weeks, resulting in mean increases of 17.3 ± 20.8 L/min and 26.2 ± 21.2 L/min, respectively. Canadian neighborhood pharmacy read more […]

Reduction of Eosinophilic Inflammation in the Airways: Sputum Eosinophils

Montelukast decreased the mean percentage of sputum eosinophils from 24.6 ± 12.3% at baseline to 15.1 ± 11.8% at the end of the treatment period, resulting in a change of — 9.5 ± 12.7% (p < 0.005). In contrast, placebo treatment decreased the mean percentage of sputum eosinophils from 21.3 ± 12.1% at baseline to 21.0 […]

Reduction of Eosinophilic Inflammation in the Airways: Data Analysis

Because this study used a crossover design, the effects of carry-over and period were evaluated. The homogeneity of background factors between the two groups was examined by x2 test (significance level, two-tailed, 15%). The changes from baseline in eosinophil percentages in sputum and peripheral blood were analyzed using an analysis of variance model including the […]

Reduction of Eosinophilic Inflammation in the Airways: Sputum Induction and Eosinophil Counts

Sputum induction was performed as described previously. Medications were stopped for at least 12 h, after which sputum was induced by inhalation of increasing concentrations of hypertonic saline solution (0.9%, 1.8%, 3%, 4%, and 5%) until an adequate volume of sputum was collected. Patients were encouraged to cough deeply after each inhalation. Cell plugs in […]

Reduction of Eosinophilic Inflammation in the Airways: Study Design

Patients receiving Chinese medicines, immunotherapy, or nonspecific therapy were also excluded from this study. None of the patients had respiratory infections within 4 weeks before enrollment, or chronic bronchitis, pulmonary emphysema, bronchiectasia, or other lung diseases that could interfere with the evaluation of the efficacy of montelukast. Patients with liver disorders, renal disorders, heart disorders, […]

Reduction of Eosinophilic Inflammation in the Airways: Materials and Methods

In 12-week, multicenter, randomized, double-blind studies in adult patients with persistent asthma, treatment with montelukast resulted in significant improvements in respiratory function, asthma symptoms, as-needed β2-agonist use, peripheral eosinophil counts, and health-related quality of life. Furthermore, Pizzichini et al demonstrated that 4 weeks of treatment with mon-telukast resulted in decreases in both sputum and peripheral […]

Reduction of Eosinophilic Inflammation in the Airways

Studies have demonstrated that asthma is associated with chronic airway inflammation with recruitment of a number of inflammatory cells, including T cells and eosinophils. Although several chemical mediators are released during chronic airway inflammation, evidence strongly suggests that the cysteinyl leukotrienes (CysLTs) C4, D4, and E4 play key roles in asthma. Leukotrienes (LTs) are not […]

Pages: Prev 1 2
anosiahuman.com